167 related articles for article (PubMed ID: 23589193)
1. Dalfampridine in patients with downbeat nystagmus--an observational study.
Claassen J; Feil K; Bardins S; Teufel J; Spiegel R; Kalla R; Schneider E; Jahn K; Schniepp R; Strupp M
J Neurol; 2013 Aug; 260(8):1992-6. PubMed ID: 23589193
[TBL] [Abstract][Full Text] [Related]
2. 4-aminopyridine restores vertical and horizontal neural integrator function in downbeat nystagmus.
Kalla R; Glasauer S; Büttner U; Brandt T; Strupp M
Brain; 2007 Sep; 130(Pt 9):2441-51. PubMed ID: 17664175
[TBL] [Abstract][Full Text] [Related]
3. Comparison of 10-mg doses of 4-aminopyridine and 3,4-diaminopyridine for the treatment of downbeat nystagmus.
Kalla R; Spiegel R; Claassen J; Bardins S; Hahn A; Schneider E; Rettinger N; Glasauer S; Brandt T; Strupp M
J Neuroophthalmol; 2011 Dec; 31(4):320-5. PubMed ID: 21734596
[TBL] [Abstract][Full Text] [Related]
4. A randomised double-blind, cross-over trial of 4-aminopyridine for downbeat nystagmus--effects on slowphase eye velocity, postural stability, locomotion and symptoms.
Claassen J; Spiegel R; Kalla R; Faldon M; Kennard C; Danchaivijitr C; Bardins S; Rettinger N; Schneider E; Brandt T; Jahn K; Teufel J; Strupp M; Bronstein A
J Neurol Neurosurg Psychiatry; 2013 Dec; 84(12):1392-9. PubMed ID: 23813743
[TBL] [Abstract][Full Text] [Related]
5. Effect of chlorzoxazone in patients with downbeat nystagmus: a pilot trial.
Feil K; Claaßen J; Bardins S; Teufel J; Krafczyk S; Schneider E; Schniepp R; Jahn K; Kalla R; Strupp M
Neurology; 2013 Sep; 81(13):1152-8. PubMed ID: 23975871
[TBL] [Abstract][Full Text] [Related]
6. Effect of 3,4-diaminopyridine on the postural control in patients with downbeat nystagmus.
Sprenger A; Zils E; Rambold H; Sander T; Helmchen C
Ann N Y Acad Sci; 2005 Apr; 1039():395-403. PubMed ID: 15826992
[TBL] [Abstract][Full Text] [Related]
7. Clinical use of 4-aminopyridine in patients with downbeat nystagmus.
Domínguez-Durán E; Mármol-Szombathy I; Baños-Roldán Ú; Sánchez-Gómez S
Acta Otorrinolaringol Esp (Engl Ed); 2020; 71(1):40-44. PubMed ID: 31078225
[TBL] [Abstract][Full Text] [Related]
8. Clinical overview of dalfampridine: an agent with a novel mechanism of action to help with gait disturbances.
Egeberg MD; Oh CY; Bainbridge JL
Clin Ther; 2012 Nov; 34(11):2185-94. PubMed ID: 23123001
[TBL] [Abstract][Full Text] [Related]
9. Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients.
Limone BL; Sidovar MF; Coleman CI
Health Qual Life Outcomes; 2013 Jun; 11():105. PubMed ID: 23799913
[TBL] [Abstract][Full Text] [Related]
10. The safety profile of dalfampridine extended release in multiple sclerosis clinical trials.
Cornblath DR; Bienen EJ; Blight AR
Clin Ther; 2012 May; 34(5):1056-69. PubMed ID: 22497693
[TBL] [Abstract][Full Text] [Related]
11. Treatment of downbeat nystagmus with 3,4-diaminopyridine: a placebo-controlled study.
Strupp M; Schüler O; Krafczyk S; Jahn K; Schautzer F; Büttner U; Brandt T
Neurology; 2003 Jul; 61(2):165-70. PubMed ID: 12874393
[TBL] [Abstract][Full Text] [Related]
12. Transition from downbeat to upbeat nystagmus caused by 4-aminopyridine.
Feil K; Claaßen J; Bardins S; Teufel J; Habs M; Kalla R; Strupp M
J Neurol; 2013 May; 260(5):1426-8. PubMed ID: 23595790
[No Abstract] [Full Text] [Related]
13. Effects of dalfampridine on attacks in patients with episodic ataxia type 2: an observational study.
Claassen J; Teufel J; Kalla R; Spiegel R; Strupp M
J Neurol; 2013 Feb; 260(2):668-9. PubMed ID: 23183922
[No Abstract] [Full Text] [Related]
14. Beneficial effects of 3,4-diaminopyridine on positioning downbeat nystagmus in a circumscribed uvulo-nodular lesion.
Helmchen C; Gottschalk S; Sander T; Trillenberg P; Rambold H; Sprenger A
J Neurol; 2007 Aug; 254(8):1126-8. PubMed ID: 17410325
[No Abstract] [Full Text] [Related]
15. Real-time computer-based visual feedback improves visual acuity in downbeat nystagmus - a pilot study.
Teufel J; Bardins S; Spiegel R; Kremmyda O; Schneider E; Strupp M; Kalla R
J Neuroeng Rehabil; 2016 Jan; 13():1. PubMed ID: 26728632
[TBL] [Abstract][Full Text] [Related]
16. Potassium channels, the cerebellum, and treatment for downbeat nystagmus.
Leigh RJ
Neurology; 2003 Jul; 61(2):158-9. PubMed ID: 12874391
[No Abstract] [Full Text] [Related]
17. Dalfampridine extended release: in multiple sclerosis.
Chwieduk CM; Keating GM
CNS Drugs; 2010 Oct; 24(10):883-91. PubMed ID: 20839898
[TBL] [Abstract][Full Text] [Related]
18. Lack of effect on ambulation of dalfampridine-ER (4-AP) treatment in adult SMA patients.
Chiriboga CA; Marra J; LaMarca NM; Young SD; Weimer LH; Levin B; McCabe B
Neuromuscul Disord; 2020 Aug; 30(8):693-700. PubMed ID: 32788051
[TBL] [Abstract][Full Text] [Related]
19. Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial.
Applebee A; Goodman AD; Mayadev AS; Bethoux F; Goldman MD; Klingler M; Blight AR; Carrazana EJ
Clin Ther; 2015 Dec; 37(12):2780-7. PubMed ID: 26565077
[TBL] [Abstract][Full Text] [Related]
20. Effect of 4-aminopyridine on gravity dependence and neural integrator function in patients with idiopathic downbeat nystagmus.
Sander T; Sprenger A; Marti S; Naumann T; Straumann D; Helmchen C
J Neurol; 2011 Apr; 258(4):618-22. PubMed ID: 21057959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
